Comparing the Effectiveness of One vs. Two JYNNEOS Doses

Abstract

Monkeypox (mpox) is a viral zoonotic disease that recently gained global attention for a potential pandemic in 2022-2023. Most cases are not very severe, but children, the elderly, pregnant people, and the immunocompromised are at a greater risk to be badly affected by this disease. Despite this, the general population may not know if it's better to stay with a single dose of the vaccine, which provides decent protection, or to get the second dosage, which, while often perceived as optional, can provide added protection. This paper explores the difference between one or two doses in preventing mpox over a 3 month period.
Multiple studies in this paper clearly demonstrate a significant disparity in effectiveness between the two dosages. A CIDRAP study found that one dose provided a 36% efficacy rate, while two doses gave a more reliable 66% efficacy rate. A later study by the CDC corroborates this data, finding that one dose gave a 68.1% efficacy rate while two doses gave one of 88.5%. Other studies, such as those from JAMA or the New England Journal of Medicine, also support this disparity, with two doses consistently outperforming a single one. 

While a single dosage of JYNNEOS provides some protection, the data have consistently shown that two doses of the vaccine are far more effective at preventing mpox. This conclusion is important for health professionals and caregivers to create an ideal vaccination regimen for their students, but is also important for individuals themselves to be able to make informed decisions on how many doses is right for them. Overall, the data strongly supports that two doses of the vaccine give much better protection from mpox than one dose does.